Literature DB >> 20644216

Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.

Cheol Whan Lee1, Chan-Sik Park, Ilseon Hwang, Youngji Kim, Duk-Woo Park, Soo-Jin Kang, Seung-Hwan Lee, Young-Hak Kim, Seong-Wook Park, Seung-Jung Park.   

Abstract

BACKGROUND: Little is known about hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase expression in human coronary atherosclerotic plaques.
OBJECTIVE: To investigate the expression of HMG-CoA reductase in coronary atherectomy tissues obtained from patients with unstable and stable angina and examine the relationship of HMG-CoA with plaque instability.
METHODS: Atherectomy specimens were obtained from 43 patients with unstable (n=22) or stable (n=21) angina who underwent directional coronary atherectomy for de novo coronary artery lesions. The specimens were stained with haematoxylin-eosin and incubated with antibodies specific to HMG-CoA reductase, macrophages, smooth muscle cells and endothelial cells. Histology and immunohistochemistry data were morphometrically evaluated using an image-analysing system.
RESULTS: Baseline characteristics were similar between the two groups. Immunopositive areas of HMG-CoA reductase, macrophages, endothelial cells and thrombi were significantly greater in patients with unstable angina than those in patients with stable angina. However, the immunopositive area of smooth muscle cells was not different between the two groups. Macrophage-positive areas correlated well with areas of HMG-CoA reductase in patients with unstable angina (r=0.72, p<0.001), but not in patients with stable angina (r=0.02, p=0.937).
CONCLUSION: HMG-CoA reductase was present in coronary atherosclerotic plaques and was more commonly expressed in unstable plaques than in stable plaques. Local HMG-CoA reductase in coronary artery lesions may contribute to plaque instability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644216     DOI: 10.1136/hrt.2009.190934

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  3 in total

1.  Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Ji Won Kim; Kyeong Ho Yun; Eun Kyoung Kim; Yong Cheol Kim; Dai-Yeol Joe; Jum Suk Ko; Sang Jae Rhee; Eun Mi Lee; Nam Jin Yoo; Nam-Ho Kim; Seok Kyu Oh; Jin-Won Jeong
Journal:  Korean Circ J       Date:  2014-03-12       Impact factor: 3.243

2.  Systemic involvement in ACS: Using CMR imaging to compare the aortic wall in patients with and without acute coronary syndrome.

Authors:  Elizabeth Chandy; Alexander Ivanov; Devindra S Dabiesingh; Alexandra Grossman; Prasanthi Sunkesula; Lakshmi Velagapudi; Virna L Sales; Edward J Colombo; Igor Klem; Terrence J Sacchi; John F Heitner
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

3.  [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action.

Authors:  Gonçalo S Clemente; Jens Rickmeier; Inês F Antunes; Tryfon Zarganes-Tzitzikas; Alexander Dömling; Tobias Ritter; Philip H Elsinga
Journal:  EJNMMI Res       Date:  2020-04-15       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.